NL-OMON38904CompletedNot Applicable
Efficacy analysis of a novel compound in a humanized mouse model for psoriasis and development of the humanized mouse model - Pre-clinical efficacy of a novel compound in psoriasis
TNO0 sites33 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 33
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Psoriasis patients: Adults (m/f) with a mild to moderate form of psoriasis vulgaris (PASI score of maximal 18 and minimum BSA of 3%). Patients are allowed to use local corticosteroids or ointments to prevent dry skin (see Appendix 2).
Exclusion Criteria
- •These patients have not received light therapy or another form of systemic treatment (methotrexate, cyclosporin A, anti-TNF treatments). Gender or age of the adults are not exclusion criteria (see Appendix 2).
Investigators
Similar Trials
Completed
Not Applicable
Efficacy analysis of a novel compound in a humanized mouse model of psoriasisflaking diseasePsoriasis1000381610014982NL-OMON37226TNO16
Completed
Not Applicable
Efficacy of two novel compounds in a humanized mouse model of psoriasisflaking diseasepsoriasis1000381610014982NL-OMON35972TNO29
Recruiting
Not Applicable
Efficacy of a three novel compounds in a humanized mouse model of psoriasisflaking diseasepsoriasis1000381610014982NL-OMON35935Pfizer24
Completed
Not Applicable
Efficacy of a proprietary compound B in a humanized mouse model of psoriasisflaking diseasepsoriasis1000381610014982NL-OMON34173TNO26
Completed
Not Applicable
A safety and efficacy study of a novel formulation of prednisolone metasulfobenzoate (predocol) in the induction of remission and maintenance in patients with ulcerative colitisAcute exacerbations of ulcerative colitisNutritional, Metabolic, EndocrineUlcerative colitisISRCTN14133410Flexpharm Ltd. (UK)180